{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P05019",
      "entity_text" : "IGF-1",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q06889",
      "entity_text" : "pilot",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Clinical pilot studies and early reports have supported the safety / preliminary efficacy of IGF-1 and related compounds in the treatment of Rett Syndrome, with evidence mounting for its use in Phelan McDermid Syndrome and Fragile X Syndrome.",
  "reading_complete" : "2020-08-05T20:01:47Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T20:00:16Z",
  "trigger" : "supported",
  "evidence" : [ "pilot studies and early reports have supported the safety/preliminary efficacy of IGF-1" ],
  "pmc_id" : "5043261",
  "score" : 0
}